Merck (MRK)
Market Price (11/5/2026): $150.67 | Market Cap: $371.7 BilInvestor Relations Sector: Health Care | Industry: Pharmaceuticals
Merck (MRK)
Market Price (11/5/2026): $150.67Market Cap: $371.7 BilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 28%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 22%, CFO LTM is 19 Bil, FCF LTM is 15 Bil Attractive yieldDividend Yield is 2.3% Stock buyback supportStock Buyback 3Y Total is 9.1 Bil Low stock price volatilityVol 12M is 30% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Show more. | Trading close to highsDist 52W High is -3.3%, Dist 3Y High is -3.3% Weak multi-year price returns3Y Excs Rtn is -21% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 55x, P/EPrice/Earnings or Price/(Net Income) is 151x Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.3% Key risksMRK key risks include [1] the impending 2028 patent expiration of its blockbuster drug, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 28%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 22%, CFO LTM is 19 Bil, FCF LTM is 15 Bil |
| Attractive yieldDividend Yield is 2.3% |
| Stock buyback supportStock Buyback 3Y Total is 9.1 Bil |
| Low stock price volatilityVol 12M is 30% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Show more. |
| Trading close to highsDist 52W High is -3.3%, Dist 3Y High is -3.3% |
| Weak multi-year price returns3Y Excs Rtn is -21% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 55x, P/EPrice/Earnings or Price/(Net Income) is 151x |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.3% |
| Key risksMRK key risks include [1] the impending 2028 patent expiration of its blockbuster drug, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Merck (MRK) stock has gained about 15% since 7/31/2026 because of the following key factors:
1. Strong Performance in Fiscal Q3 2026 and Upgraded Financial Outlook.
Merck reported robust financial results for its fiscal third quarter ended September 30, 2026, significantly surpassing analyst expectations. The company announced adjusted earnings per share (EPS) of $2.49, exceeding the consensus estimate of $2.09, and total worldwide sales of $18.1 billion, above the $17.28 billion forecast. Following these strong results, Merck raised and narrowed its full-year 2026 non-GAAP EPS guidance to a range of $2.77 to $2.82, up from its previous outlook of $2.66 to $2.76, and updated its sales forecast to between $66.8 billion and $67.3 billion. This positive financial performance and outlook boosted investor confidence.
2. Continued Growth of Key Oncology Products and Successful New Launches.
Merck's flagship cancer immunotherapy, Keytruda, continued its strong sales trajectory, with the Keytruda family of products generating $8.6 billion in sales in fiscal Q3 2026, representing a 6% increase. Notably, the newer subcutaneous formulation, Keytruda QLEX, contributed $830 million to these sales. Beyond Keytruda, the pulmonary arterial hypertension treatment Winrevair demonstrated exceptional growth, with sales surging 93% year-over-year to $694 million in the third quarter. The HPV vaccine Gardasil also saw strong sales, rising 14% excluding currency effects to approximately $2 billion. These strong sales performances from both established blockbusters and newer products underscored Merck's diversified growth strategy.
Show more
Merck (MRK) stock has gained about 15% since 7/31/2026 because of the following key factors:
1. Strong Performance in Fiscal Q3 2026 and Upgraded Financial Outlook.
Merck reported robust financial results for its fiscal third quarter ended September 30, 2026, significantly surpassing analyst expectations. The company announced adjusted earnings per share (EPS) of $2.49, exceeding the consensus estimate of $2.09, and total worldwide sales of $18.1 billion, above the $17.28 billion forecast. Following these strong results, Merck raised and narrowed its full-year 2026 non-GAAP EPS guidance to a range of $2.77 to $2.82, up from its previous outlook of $2.66 to $2.76, and updated its sales forecast to between $66.8 billion and $67.3 billion. This positive financial performance and outlook boosted investor confidence.
2. Continued Growth of Key Oncology Products and Successful New Launches.
Merck's flagship cancer immunotherapy, Keytruda, continued its strong sales trajectory, with the Keytruda family of products generating $8.6 billion in sales in fiscal Q3 2026, representing a 6% increase. Notably, the newer subcutaneous formulation, Keytruda QLEX, contributed $830 million to these sales. Beyond Keytruda, the pulmonary arterial hypertension treatment Winrevair demonstrated exceptional growth, with sales surging 93% year-over-year to $694 million in the third quarter. The HPV vaccine Gardasil also saw strong sales, rising 14% excluding currency effects to approximately $2 billion. These strong sales performances from both established blockbusters and newer products underscored Merck's diversified growth strategy.
3. Positive Late-Stage Oncology Pipeline Updates, Bolstering Post-Keytruda Outlook.
Significant positive news from Merck's oncology pipeline substantially de-risked its long-term growth prospects beyond Keytruda's eventual loss of exclusivity. In August, the company announced positive Phase 3 results for its personalized mRNA cancer vaccine, intismeran autogene, in combination with Keytruda for adjuvant treatment of resected melanoma. This news alone caused Merck's shares to jump 12% in August, as the data showed a 42% reduction in the risk of melanoma death or recurrence. Further positive data were presented at the European Society for Medical Oncology (ESMO) Congress 2026 in October, including the first positive Phase 3 results for sacituzumab tirumotecan (sac-TMT) in advanced or recurrent endometrial cancer, demonstrating a 41% reduction in the risk of disease progression or death and a 32% reduction in the risk of death. These pipeline advancements reinforce confidence in Merck's future portfolio.
4. U.S. FDA Approval of LIPFENDRA.
In early August, Merck received U.S. FDA approval for LIPFENDRA (enlicitide), a significant milestone as it represents the first and only once-daily oral PCSK9 inhibitor for reducing LDL-C in adults with hypercholesterolemia. This approval opens a new cardiometabolic treatment opportunity and marks an important addition to Merck's portfolio, contributing to the company's broader pipeline diversification efforts.
Show less
Stock Movement Drivers
Fundamental Drivers
The 16.2% change in MRK stock from 7/31/2026 to 11/4/2026 was primarily driven by a 322.4% change in the company's P/E Multiple.| (LTM values as of) | 7312026 | 11042026 | Change |
|---|---|---|---|
| Stock Price ($) | 129.44 | 150.36 | 16.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 65,768 | 67,378 | 2.4% |
| Net Income Margin (%) | 13.6% | 3.6% | -73.2% |
| P/E Multiple | 35.8 | 151.3 | 322.4% |
| Shares Outstanding (Mil) | 2,472 | 2,468 | 0.2% |
| Cumulative Contribution | 16.2% |
Market Drivers
7/31/2026 to 11/4/2026| Return | Correlation | |
|---|---|---|
| MRK | 16.2% | |
| Market (SPY) | 2.6% | 10.3% |
| Sector (XLV) | 16.7% | 68.0% |
Fundamental Drivers
The 39.5% change in MRK stock from 4/30/2026 to 11/4/2026 was primarily driven by a 932.8% change in the company's P/E Multiple.| (LTM values as of) | 4302026 | 11042026 | Change |
|---|---|---|---|
| Stock Price ($) | 107.76 | 150.36 | 39.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 65,011 | 67,378 | 3.6% |
| Net Income Margin (%) | 28.1% | 3.6% | -87.0% |
| P/E Multiple | 14.6 | 151.3 | 932.8% |
| Shares Outstanding (Mil) | 2,481 | 2,468 | 0.5% |
| Cumulative Contribution | 39.5% |
Market Drivers
4/30/2026 to 11/4/2026| Return | Correlation | |
|---|---|---|
| MRK | 39.5% | |
| Market (SPY) | 7.0% | -2.1% |
| Sector (XLV) | 30.5% | 68.8% |
Fundamental Drivers
The 80.0% change in MRK stock from 10/31/2025 to 11/4/2026 was primarily driven by a 1083.8% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 11042026 | Change |
|---|---|---|---|
| Stock Price ($) | 83.53 | 150.36 | 80.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 63,616 | 67,378 | 5.9% |
| Net Income Margin (%) | 25.8% | 3.6% | -85.9% |
| P/E Multiple | 12.8 | 151.3 | 1083.8% |
| Shares Outstanding (Mil) | 2,510 | 2,468 | 1.7% |
| Cumulative Contribution | 80.0% |
Market Drivers
10/31/2025 to 11/4/2026| Return | Correlation | |
|---|---|---|
| MRK | 80.0% | |
| Market (SPY) | 13.4% | 5.6% |
| Sector (XLV) | 33.2% | 66.1% |
Fundamental Drivers
The 60.4% change in MRK stock from 10/31/2023 to 11/4/2026 was primarily driven by a 97.8% change in the company's P/E Multiple.| (LTM values as of) | 10312023 | 11042026 | Change |
|---|---|---|---|
| Stock Price ($) | 93.72 | 150.36 | 60.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 58,311 | 67,378 | 15.5% |
| Net Income Margin (%) | 5.3% | 3.6% | -31.8% |
| P/E Multiple | 76.5 | 151.3 | 97.8% |
| Shares Outstanding (Mil) | 2,539 | 2,468 | 2.9% |
| Cumulative Contribution | 60.4% |
Market Drivers
10/31/2023 to 11/4/2026| Return | Correlation | |
|---|---|---|
| MRK | 60.4% | |
| Market (SPY) | 89.7% | 16.0% |
| Sector (XLV) | 59.5% | 62.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MRK Return | 2% | 49% | 1% | -6% | 10% | 46% | 130% |
| Peers Return | 36% | 15% | -3% | 12% | 24% | 31% | 176% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 11% | 102% |
Monthly Win Rates [3] | |||||||
| MRK Win Rate | 42% | 67% | 42% | 33% | 50% | 73% | |
| Peers Win Rate | 62% | 63% | 40% | 53% | 62% | 69% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 36% | |
Max Drawdowns [4] | |||||||
| MRK Max Drawdown | -20% | -11% | -14% | -27% | -27% | -11% | |
| Peers Max Drawdown | -17% | -19% | -26% | -20% | -23% | -16% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: PFE, JNJ, LLY, ABBV, BMY. See MRK Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/4/2026 (YTD)
How Low Can It Go
| Event | MRK | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -13.4% | -18.8% |
| % Gain to Breakeven | 15.5% | 23.1% |
| Time to Breakeven | 71 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -12.7% | -7.8% |
| % Gain to Breakeven | 14.5% | 8.5% |
| Time to Breakeven | 549 days | 18 days |
| 2020 COVID-19 Crash | ||
| % Loss | -18.4% | -33.7% |
| % Gain to Breakeven | 22.5% | 50.9% |
| Time to Breakeven | 16 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -18.2% | -12.2% |
| % Gain to Breakeven | 22.3% | 13.9% |
| Time to Breakeven | 277 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -16.2% | -6.8% |
| % Gain to Breakeven | 19.4% | 7.3% |
| Time to Breakeven | 204 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -17.4% | -17.9% |
| % Gain to Breakeven | 21.1% | 21.8% |
| Time to Breakeven | 93 days | 123 days |
In The Past
Merck's stock fell -13.4% during the 2025 US Tariff Shock. Such a loss loss requires a 15.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | MRK | S&P 500 |
|---|---|---|
| 2008-2009 Global Financial Crisis | ||
| % Loss | -62.5% | -53.4% |
| % Gain to Breakeven | 166.4% | 114.4% |
| Time to Breakeven | 1319 days | 1085 days |
In The Past
Merck's stock fell -13.4% during the 2025 US Tariff Shock. Such a loss loss requires a 15.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Merck (MRK)
Merck & Co., Inc. (MRK) operates as a global healthcare company, dedicated to improving health for both humans and animals. Its business is strategically divided into two primary segments: Pharmaceutical and Animal Health. This structure allows Merck to develop and deliver a comprehensive range of health solutions worldwide, underpinned by extensive research and manufacturing capabilities.
The Pharmaceutical segment focuses on human health, offering a robust portfolio of prescription medicines and vaccines. Its key product areas include oncology, immunology, neuroscience, virology, cardiovascular, diabetes, and hospital acute care, alongside vital preventive vaccines for all age groups. Merck distributes these products to a wide array of customers, including drug wholesalers and retailers, hospitals, government agencies, managed health care providers, and directly to physicians.
Complementing its human health focus, Merck's Animal Health segment provides innovative veterinary pharmaceuticals, vaccines, and health management solutions. This segment also develops advanced digitally connected products for animal identification, traceability, and monitoring. By serving veterinarians and animal producers globally, Merck contributes to animal well-being and livestock productivity.
AI Analysis | Feedback
Here are 1-3 brief analogies for Merck (MRK):
- Like Pfizer, but with a significant focus on animal health in addition to human pharmaceuticals.
- Similar to the pharmaceutical and vaccine divisions of Johnson & Johnson, plus a major animal health business.
AI Analysis | Feedback
- Human Pharmaceutical Products: Merck develops and markets pharmaceutical drugs targeting various human diseases, including oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes.
- Human Vaccine Products: The company offers a range of vaccine products for the prevention of diseases in pediatric, adolescent, and adult populations.
- Veterinary Pharmaceutical Products: Merck discovers, develops, manufactures, and markets medicinal pharmaceuticals for animal health.
- Animal Vaccines: The company provides vaccines specifically designed to protect animals from various diseases.
- Animal Health Management Solutions and Services: Merck offers health management solutions and services aimed at improving the overall well-being and productivity of animals.
- Digitally Connected Animal Identification & Monitoring Products: The company provides digital products for the identification, traceability, and monitoring of animals.
AI Analysis | Feedback
Merck (MRK) primarily sells its products to other companies and organizations rather than directly to individuals. Based on the company description, its major customers are intermediaries and healthcare providers. While specific customer names are not provided in the background, the following public companies represent typical major customers within the described categories:
Drug Wholesalers
These companies act as major distributors of pharmaceutical products from manufacturers like Merck to pharmacies, hospitals, and other healthcare providers.
- McKesson Corporation (MCK)
- AmerisourceBergen Corporation (ABC)
- Cardinal Health, Inc. (CAH)
Retail Pharmacies
Large pharmacy chains are significant purchasers and distributors of Merck's pharmaceutical products to the end consumer.
- CVS Health Corporation (CVS)
- Walgreens Boots Alliance, Inc. (WBA)
Managed Health Care Providers and Pharmacy Benefit Managers (PBMs)
These organizations manage healthcare plans and prescription drug benefits for large populations, influencing drug purchasing and formularies.
- UnitedHealth Group Inc. (UNH)
- The Cigna Group (CI)
- Elevance Health, Inc. (ELV)
Hospital Systems
Large hospital networks directly procure a range of pharmaceutical products for patient care.
- HCA Healthcare, Inc. (HCA)
AI Analysis | Feedback
AI Analysis | Feedback
Robert M. Davis, Chairman and Chief Executive Officer
Robert M. Davis is the Chairman of the Board and Chief Executive Officer of Merck & Co., Inc.. He joined Merck in 2014 as the Chief Financial Officer, with additional responsibilities for real estate operations, corporate strategy, and business development. In 2016, his role expanded to include information technology and procurement, forming Global Services. He became President in April 2021, and then CEO and a member of the board of directors on July 1, 2021. Prior to joining Merck, Mr. Davis was corporate vice president and president of Baxter’s medical products business. During his time at Baxter, he also held positions such as president of Baxter's renal business, chief financial officer, and treasurer. Before his tenure at Baxter, he spent 14 years at Eli Lilly and Company in various roles of increasing responsibility, including Director of Corporate Financial Planning.
Caroline Litchfield, Executive Vice President and Chief Financial Officer
Caroline Litchfield serves as the Executive Vice President and Chief Financial Officer for Merck, overseeing the company's finance, procurement, and real estate operations. She began her career at Merck in 1990 within its U.K. business and has since held numerous positions of increasing responsibility in country, regional, and global finance functions. Ms. Litchfield previously served as the company's treasurer, responsible for treasury, tax, and investor relations. From 2014 to 2018, she led finance for Human Health, Merck's largest business. She was also instrumental in the integration of Merck and Schering-Plough after their 2009 merger, serving as vice president and finance lead for the Emerging Markets region. She was appointed Executive Vice President and CFO, effective April 1, 2021. In June 2024, she was elected to the board of directors for Verizon.
Dean Y. Li, M.D., Ph.D., Executive Vice President and President, Merck Research Laboratories
Dean Y. Li is the Executive Vice President and President of Merck Research Laboratories, where he leads the company's global human vaccines and therapeutics research and development organization. He joined Merck in 2017, taking on leadership roles within the Translational Medicine and Discovery functions. Dr. Li was appointed President of Merck Research Laboratories in January 2021. Before joining Merck, he held positions of increasing responsibility in translational medical research at the University of Utah.
Sanat Chattopadhyay, Executive Vice President and President, Merck Manufacturing Division
Sanat Chattopadhyay is the Executive Vice President and President of the Merck Manufacturing Division. His professional background includes experience with companies such as Pfizer and Sanofi. He has an educational background that includes studies at Jadavpur University and NITIE.
Richard R. DeLuca, Jr., Executive Vice President and President, Merck Animal Health
Richard R. DeLuca, Jr. holds the position of Executive Vice President and President of Merck Animal Health.
AI Analysis | Feedback
- Keytruda Patent Cliff: The most significant risk for Merck is the impending patent expiration of its flagship oncology drug, Keytruda (pembrolizumab). Keytruda's primary U.S. patents are set to expire in late 2028, with some extensions potentially pushing exclusivity to 2029. This drug is a major revenue driver for Merck, accounting for nearly half of its pharmaceutical sales in 2024 and 40% in 2023. Analysts project Keytruda sales to peak around $33–34 billion in 2028, followed by a substantial decline of approximately 19% to about $27.4 billion by 2029 as biosimilars enter the U.S. market. Merck is actively pursuing mitigation strategies, including developing a subcutaneous formulation (Keytruda Qlex) that received FDA approval in September 2025, which may help retain patient loyalty and extend some protection, possibly until 2040 or longer for specific formulations. The company is also implementing a $3 billion cost-cutting initiative and investing in new product launches and pipeline development to offset the anticipated revenue decline.
- Loss of Exclusivity for Other Key Products: Beyond Keytruda, Merck faces a broader "loss-of-exclusivity (LOE) wave" for several other significant pharmaceutical products between 2025 and 2029, putting nearly half of its 2024 pharmaceutical revenue at risk. Notably, Januvia/Janumet, Lenvima (in partnership with Eisai), and Gardasil 9 are also facing patent expirations or generic competition around the same period. For instance, U.S. generics for Januvia are expected by mid-2026, and Gardasil 9 U.S. patents expire in 2028. This collective expiration of patents on major revenue-generating drugs presents a significant challenge to Merck's market share and overall revenues.
- Regulatory Changes and Pricing Pressures: Merck, as a global pharmaceutical company, is continuously subject to evolving and increasingly stringent regulatory requirements, particularly concerning drug pricing and reimbursement. With rising global healthcare expenditures, governments worldwide are increasing pressure on pharmaceutical companies, which can negatively impact product profitability and the success of market launches. The Inflation Reduction Act (IRA) in the U.S., for example, includes Medicare price cuts that are active from January 2028, further contributing to pricing pressures.
AI Analysis | Feedback
- The rapid advancement and expansion of mRNA technology by competitors, potentially displacing Merck's traditional vaccine platforms and certain therapeutic areas.
- The implementation and potential expansion of government-mandated drug price negotiation (e.g., under the U.S. Inflation Reduction Act), which threatens the profitability and R&D investment model for Merck's pharmaceutical products.
AI Analysis | Feedback
Merck (MRK) operates in diverse healthcare markets, with substantial addressable markets for its main products and services across both its Pharmaceutical and Animal Health segments.
Pharmaceutical Segment
- Oncology: The global oncology market size was estimated at approximately USD 225.01 billion in 2024 and is projected to reach around USD 668.26 billion by 2034. North America held approximately a 46% share of this market in 2024.
- Hospital Acute Care: The global acute hospital care market generated a revenue of USD 3,344,042.1 million (or USD 3.34 trillion) in 2023 and is expected to reach USD 4,903,896.5 million (or USD 4.9 trillion) by 2030. North America was the largest revenue-generating market in 2023, accounting for 55.8% of the global market.
- Immunology: The global immunology market size was valued at USD 108.40 billion in 2024 and is estimated to hit around USD 286.38 billion by 2034. In 2024, North America dominated the global market with the largest share of 53%.
- Neuroscience: The global neuroscience market generated a revenue of USD 44,653.7 million in 2023 and is expected to reach USD 65,224.5 million by 2030. North America was the largest revenue-generating market in 2023.
- Virology: The global virology market size was valued at USD 2.55 billion in 2024 and is projected to reach USD 4.51 billion by 2033. North America was the largest contributor to this market in 2024.
- Cardiovascular: The global cardiovascular drugs market size is calculated at USD 155.96 billion in 2025 and is predicted to increase to approximately USD 214.72 billion by 2034.
- Diabetes: The global diabetes drugs market size was valued at USD 101.48 billion in 2025 and is projected to grow to USD 283.36 billion by 2034. North America dominated the diabetes drugs market with a market share of 49.95% in 2025.
- Vaccines (Human Health): The global human vaccines market was valued at USD 82.80 billion in 2024 and is expected to reach USD 186.73 billion by 2032. North America dominated the vaccine market with the largest revenue share of 38.3% in 2024.
Animal Health Segment
- Veterinary Pharmaceuticals, Vaccines, and Health Management Solutions: The global animal health market size was valued at USD 67.92 Billion in 2024 and is poised to grow to USD 128.05 Billion by 2033. North America held a significant market share of 44.9% in 2025.
AI Analysis | Feedback
Merck (MRK) anticipates several key drivers to fuel its future revenue growth over the next two to three years:
- Accelerated Launch of New Products and Pipeline Expansion: Merck is intensifying its efforts to launch new drugs and has substantially expanded its late-stage pipeline. The company projects approximately $50 billion in revenue from new growth drivers by the early 2030s, contributing to a target of $70 billion by the mid-2030s. This includes a focus on 10 major programs, all identified as multibillion-dollar opportunities, with several already launched or having positive Phase III clinical trial data.
- Growth in Cardiometabolic and Respiratory Treatments: This therapeutic area is expected to be a significant contributor to future sales, with Merck forecasting nearly $20 billion from these treatments, an increase from previous estimates. New products like Winrevair, particularly for pulmonary arterial hypertension, are anticipated to drive sustained growth.
- Expansion in Infectious Disease Medications: Merck has significantly raised its projections for infectious disease drugs, expecting them to generate approximately $15 billion in sales, a substantial increase from earlier forecasts.
- Sustained Performance and Pipeline Augmentation in Oncology: While Keytruda continues to be a major revenue driver, particularly with increased uptake in earlier-stage cancers and strong international demand, Merck is actively fortifying its oncology pipeline through new product launches and strategic acquisitions to mitigate the impact of future patent expirations. Products like Welireg are also noted as growth drivers.
- Continued Growth in the Animal Health Segment: The Animal Health segment is consistently identified as a source of revenue growth, propelled by strong demand for companion animal products, such as the Bravecto line, favorable pricing strategies, and increased demand for livestock products. Acquisitions, such as the Elanco aqua business, are also expected to contribute to this segment's expansion.
AI Analysis | Feedback
Capital Allocation Decisions of Merck (MRK) (2021-2025)
Share Repurchases
- Merck's Board of Directors authorized a new $10 billion stock repurchase program in January 2025, with no specified expiration date.
- The company executed annual share buybacks of $1.346 billion in 2023 and $1.306 billion in 2024.
- For the full year 2025, Merck's total share repurchases amounted to approximately $5.13 billion.
Inbound Investments
- In November 2025, Merck secured $700 million in non-refundable funding from Blackstone Life Sciences to support the development of sacituzumab tirumotecan (sac-TMT), an investigational antibody-drug conjugate for various cancer types.
Outbound Investments
- Merck acquired Acceleron Pharma for $11.5 billion in September 2021.
- In April 2023, the company acquired Prometheus Biosciences for $10.8 billion.
- Merck announced an agreement in early July 2025 to acquire Verona Pharma for approximately $10 billion.
Capital Expenditures
- Merck's capital expenditures increased from $3.123 billion in 2023 to $3.475 billion in 2024.
- For the full fiscal year 2025, investment spending included $4.11 billion in capital expenditures.
- The company intends to reinvest savings from a multi-year optimization initiative into higher-growth areas of its pipeline development and to expand its long-term product portfolio.
Peer Outperformance in Pharmaceuticals
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 13.4% | 63.7% | 103.3% | CAH 490% · MCK 391% · COR 194% |
| Health Care Services | 20 | 44.0% | 33.3% | 11.6% | HIMS 220% · RDNT 148% · DGX 96% |
| Managed Health Care | 8 | 44.6% | 5.6% | 0.6% | OSCR 107% · HQY 59% · ELV 11% |
| Health Care Facilities | 25 | 16.9% | 18.4% | -3.0% | THC 302% · NHC 241% · EHC 202% |
| Health Care Equipment | 50 | 14.4% | 18.7% | -15.0% | UFPT 408% · GKOS 348% · PLSE 147% |
| Pharmaceuticals ← | 60 | -5.1% | 8.2% | -35.2% | LQDA 999% · KNSA 546% · LLY 448% |
| Health Care Supplies | 11 | 34.9% | 23.0% | -36.1% | LNTH 267% · HAE 76% · MMSI 33% |
| Life Sciences Tools & Services | 108 | -6.2% | -10.3% | -74.1% | AXGN 288% · NTRA 253% · MEDP 189% |
| Biotechnology | 364 | -21.1% | -31.5% | -81.7% | ELVN 1112% · TRVI 1046% · DNTH 930% |
| Health Care Technology | 21 | -23.4% | -56.5% | -82.3% | VEEV -3% · DOCS -52% |
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 213.53 |
| Mkt Cap | 447.0 |
| Rev LTM | 66,696 |
| Op Inc LTM | 20,186 |
| FCF LTM | 13,266 |
| FCF 3Y Avg | 13,504 |
| CFO LTM | 19,396 |
| CFO 3Y Avg | 17,795 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.3% |
| Rev Chg 3Y Avg | 5.1% |
| Rev Chg Q | 6.4% |
| QoQ Delta Rev Chg LTM | 1.6% |
| Op Inc Chg LTM | 17.9% |
| Op Inc Chg 3Y Avg | 18.8% |
| Op Mgn LTM | 27.7% |
| Op Mgn 3Y Avg | 24.4% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 27.0% |
| CFO/Rev 3Y Avg | 27.4% |
| FCF/Rev LTM | 19.1% |
| FCF/Rev 3Y Avg | 21.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 447.0 |
| P/S | 6.1 |
| P/Op Inc | 24.0 |
| P/EBIT | 30.8 |
| P/E | 44.8 |
| P/CFO | 22.7 |
| Total Yield | 4.3% |
| Dividend Yield | 2.3% |
| FCF Yield 3Y Avg | 4.8% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 10.5% |
| 3M Rtn | 18.9% |
| 6M Rtn | 29.4% |
| 12M Rtn | 49.1% |
| 3Y Rtn | 79.3% |
| 1M Excs Rtn | 13.1% |
| 3M Excs Rtn | 19.8% |
| 6M Excs Rtn | 26.6% |
| 12M Excs Rtn | 38.2% |
| 3Y Excs Rtn | 1.0% |
Comparison Analyses
Clinical Pipeline
| Drug Candidate | Indication | Phase 3 Trials | Est. Primary Completion |
|---|---|---|---|
| Pembrolizumab (MK-3475) | Various cancers | 22 | Sep 2026 |
| Belzutifan (MK-6482) | Renal cell carcinoma | 8 | Oct 2026 |
| Sacituzumab Tirumotecan (MK-2870) | Advanced solid tumors | 17 | Jan 2027 |
| Nemtabrutinib (MK-1026) | Chronic lymphocytic leukemia | 3 | May 2027 |
| Suvorexant (MK-4305) | Insomnia in opioid use disorder | 1 | Jun 2027 |
| MK-8527 | HIV pre-exposure prophylaxis | 2 | Jul 2027 |
| Bomedemstat (MK-3543) | Myeloproliferative neoplasms | 3 | Jul 2027 |
| 9-Valent Human Papillomavirus Vaccine (V503) | Prevention of human papillomavirus infection | 6 | Aug 2027 |
| Zilovertamab Vedotin (MK-2140) | Diffuse large B-cell lymphoma | 2 | Sep 2027 |
| Opevesostat (MK-5684) | Prostate cancer | 2 | May 2028 |
| ... |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Pharmaceutical | 58,142 | 57,400 | 53,583 | 52,005 | 42,754 |
| Animal Health | 6,354 | 5,877 | 5,625 | 5,550 | 5,568 |
| Other | 515 | 891 | 907 | 1,728 | 382 |
| Total | 65,011 | 64,168 | 60,115 | 59,283 | 48,704 |
| $ Mil | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|
| Pharmaceutical | 21,658 | 22,164 | 22,983 | 25,852 | 25,617 |
| Other segment | 1,659 | 2,546 | 3,094 | ||
| Other | 810 | 539 | 19 | 26 | 90 |
| Corporate | -17,199 | -19,579 | -19,736 | -19,429 | -20,260 |
| All other segment revenues | 3,163 | 2,703 | |||
| Total | 6,928 | 5,670 | 6,360 | 9,612 | 8,150 |
Price Behavior
| Market Price | $150.36 | |
| Market Cap ($ Bil) | 371.1 | |
| First Trading Date | 01/02/1970 | |
| Distance from 52W High | -3.3% | |
| 50 Days | 200 Days | |
| DMA Price | $146.31 | $126.12 |
| DMA Trend | up | up |
| Distance from DMA | 2.8% | 19.2% |
| 3M | 1YR | |
| Volatility | 37.6% | 30.1% |
| Downside Capture | 43.54 | -10.57 |
| Upside Capture | 131.71 | 61.79 |
| Correlation (S&P 500) | 8.7% | 5.0% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.78 | -0.01 | 0.18 | -0.14 | 0.10 | 0.28 |
| Up Beta | -1.28 | 1.02 | -1.21 | -1.01 | 0.28 | 0.35 |
| Down Beta | -1.27 | -1.11 | -0.66 | -0.39 | -0.39 | 0.30 |
| Up Capture | -32% | 25% | 106% | 47% | 44% | 8% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 11 | 21 | 33 | 67 | 133 | 383 |
| Down Capture | -75% | 10% | 28% | -31% | -26% | 29% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 11 | 22 | 31 | 59 | 118 | 367 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MRK | |
|---|---|---|---|---|
| MRK | 88.1% | 30.1% | 2.09 | - |
| Sector ETF (XLV) | 33.1% | 16.7% | 1.53 | 66.8% |
| Equity (SPY) | 13.2% | 12.9% | 0.68 | 5.8% |
| Gold (GLD) | 1.0% | 28.8% | 0.03 | 13.0% |
| Commodities (DBC) | 35.9% | 21.2% | 1.34 | -15.3% |
| Real Estate (VNQ) | 14.3% | 14.1% | 0.70 | 37.6% |
| Bitcoin (BTCUSD) | -28.2% | 43.4% | -0.65 | -1.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MRK | |
|---|---|---|---|---|
| MRK | 16.5% | 24.9% | 0.58 | - |
| Sector ETF (XLV) | 9.3% | 15.3% | 0.40 | 58.5% |
| Equity (SPY) | 12.5% | 17.2% | 0.55 | 18.8% |
| Gold (GLD) | 17.3% | 19.1% | 0.73 | 3.7% |
| Commodities (DBC) | 8.0% | 19.6% | 0.29 | -3.1% |
| Real Estate (VNQ) | 1.8% | 18.9% | -0.01 | 26.0% |
| Bitcoin (BTCUSD) | 5.5% | 51.5% | 0.29 | 4.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MRK | |
|---|---|---|---|---|
| MRK | 13.2% | 23.5% | 0.52 | - |
| Sector ETF (XLV) | 12.5% | 16.8% | 0.61 | 64.7% |
| Equity (SPY) | 15.4% | 18.0% | 0.73 | 37.3% |
| Gold (GLD) | 11.9% | 16.5% | 0.59 | 4.3% |
| Commodities (DBC) | 7.4% | 18.1% | 0.33 | 7.5% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.23 | 36.6% |
| Bitcoin (BTCUSD) | 61.0% | 66.2% | 1.01 | 5.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 11/3/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/29/2026 | 3.8% | ||
| 8/4/2026 | 0.2% | 2.5% | 17.3% |
| 4/30/2026 | -1.6% | 2.4% | 7.0% |
| 2/3/2026 | 2.2% | 3.8% | 6.1% |
| 10/30/2025 | -0.3% | -2.5% | 17.6% |
| 7/29/2025 | -1.7% | -5.0% | 1.1% |
| 4/24/2025 | 1.4% | 8.2% | -1.1% |
| 2/4/2025 | -9.1% | -13.4% | -6.6% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 11 | 10 |
| # Negative | 13 | 12 | 13 |
| Median Positive | 2.2% | 3.8% | 6.5% |
| Median Negative | -1.8% | -3.8% | -2.2% |
| Max Positive | 6.1% | 8.8% | 17.6% |
| Max Negative | -9.8% | -13.4% | -8.8% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/29/2026 | 3.8% | ||
| 8/4/2026 | 0.2% | 2.5% | 17.3% |
| 4/30/2026 | -1.6% | 2.4% | 7.0% |
| 2/3/2026 | 2.2% | 3.8% | 6.1% |
| 10/30/2025 | -0.3% | -2.5% | 17.6% |
| 7/29/2025 | -1.7% | -5.0% | 1.1% |
| 4/24/2025 | 1.4% | 8.2% | -1.1% |
| 2/4/2025 | -9.1% | -13.4% | -6.6% |
| 10/31/2024 | -2.4% | -3.9% | -3.0% |
| 7/30/2024 | -9.8% | -12.1% | -8.8% |
| 4/25/2024 | 2.9% | 1.4% | 3.2% |
| 2/1/2024 | 4.6% | 5.5% | 5.1% |
| 10/26/2023 | 1.9% | -0.8% | -1.7% |
| 8/1/2023 | -1.3% | -0.5% | 3.1% |
| 4/27/2023 | 1.5% | 4.2% | -1.0% |
| 2/2/2023 | -3.3% | -0.3% | -0.1% |
| 10/27/2022 | 1.4% | 1.0% | 9.2% |
| 7/28/2022 | -1.4% | -4.0% | -1.1% |
| 4/28/2022 | 4.9% | 4.9% | 9.4% |
| 2/3/2022 | -3.7% | -6.7% | -5.1% |
| 10/28/2021 | 6.1% | 8.8% | -2.9% |
| 7/29/2021 | -1.8% | -3.6% | -2.2% |
| 4/29/2021 | -4.4% | 0.8% | -1.5% |
| 2/4/2021 | -1.7% | -3.1% | -5.4% |
| SUMMARY STATS | |||
| # Positive | 11 | 11 | 10 |
| # Negative | 13 | 12 | 13 |
| Median Positive | 2.2% | 3.8% | 6.5% |
| Median Negative | -1.8% | -3.8% | -2.2% |
| Max Positive | 6.1% | 8.8% | 17.6% |
| Max Negative | -9.8% | -13.4% | -8.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 11/04/2026 | 10-Q |
| 06/30/2026 | 08/07/2026 | 10-Q |
| 03/31/2026 | 05/04/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/02/2025 | 10-Q |
| 12/31/2024 | 02/25/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/05/2024 | 10-Q |
| 03/31/2024 | 05/03/2024 | 10-Q |
| 12/31/2023 | 02/26/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/05/2023 | 10-Q |
| 12/31/2022 | 02/24/2023 | 10-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 11/04/2026 | 10-Q |
| 06/30/2026 | 08/07/2026 | 10-Q |
| 03/31/2026 | 05/04/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/02/2025 | 10-Q |
| 12/31/2024 | 02/25/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/05/2024 | 10-Q |
| 03/31/2024 | 05/03/2024 | 10-Q |
| 12/31/2023 | 02/26/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/05/2023 | 10-Q |
| 12/31/2022 | 02/24/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 02/25/2022 | 10-K |
| 09/30/2021 | 11/05/2021 | 10-Q |
| 06/30/2021 | 08/09/2021 | 10-Q |
| 03/31/2021 | 05/05/2021 | 10-Q |
| 12/31/2020 | 02/25/2021 | 10-K |
| 09/30/2020 | 11/05/2020 | 10-Q |
| 06/30/2020 | 08/05/2020 | 10-Q |
| 03/31/2020 | 05/06/2020 | 10-Q |
| 12/31/2019 | 02/26/2020 | 10-K |
Recent Forward Guidance
Updated 10/30/2026Latest: Q3 2026 Earnings Reported 10/29/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Non-GAAP Other (income) expense, net | Reported | 1.40 Bil | -200.0% | Raised | Guidance: -1.40 Bil for 2026 | |||
| 2026 Sales | Reported | 66.80 Bil | 67.05 Bil | 67.30 Bil | 0.4% | Raised | Guidance: 66.80 Bil for 2026 | |
| 2026 Non-GAAP Gross margin | Reported | 81.0% | 0.0% | Affirmed | Guidance: 81.0% for 2026 | |||
| 2026 Non-GAAP Operating expenses | Reported | 42.40 Bil | 42.65 Bil | 42.90 Bil | 0.7% | Raised | Guidance: 42.35 Bil for 2026 | |
| 2026 Non-GAAP Effective income tax rate | Reported | 32.0% | 32.5% | 33.0% | -3.0% | Lowered | Guidance: 35.5% for 2026 | |
| 2026 Non-GAAP EPS | Reported | 2.77 | 2.8 | 2.82 | 3.1% | Raised | Guidance: 2.71 for 2026 | |
| 2026 Share count (assuming dilution) | Reported | 2.48 Bil | ||||||
Prior: Q2 2026 Earnings Reported 8/4/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Non-GAAP Other (income) expense, net | Reported | -1.40 Bil | ||||||
| 2026 Revenue | Reported | 66.30 Bil | 66.80 Bil | 67.30 Bil | 0.6% | Raised | Guidance: 66.40 Bil for 2026 | |
| 2026 Non-GAAP Gross Margin | Reported | 81.0% | -1.0% | Lowered | Guidance: 82.0% for 2026 | |||
| 2026 Non-GAAP Operating Expenses | Reported | 42.00 Bil | 42.35 Bil | 42.70 Bil | 16.3% | Raised | Guidance: 36.40 Bil for 2026 | |
| 2026 Non-GAAP Effective income tax rate | Reported | 35.0% | 35.5% | 36.0% | 11.5% | Raised | Guidance: 24.0% for 2026 | |
| 2026 Non-GAAP EPS | Reported | 2.66 | 2.71 | 2.76 | -46.9% | Lowered | Guidance: 5.1 for 2026 | |
Q1 2026 Earnings Reported 4/30/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Sales | Reported | 65.80 Bil | 66.40 Bil | 67.00 Bil | 0.2% | Raised | Guidance: 66.25 Bil for 2026 | |
| 2026 Gross Profit | Calculated | 53.96 Bil | 54.45 Bil | 54.94 Bil | Rev x Gross Margin | |||
| 2026 Non-GAAP Gross margin | Reported | 82.0% | 0 | Affirmed | Guidance: 82.0% for 2026 | |||
| 2026 Non-GAAP Operating expenses | Reported | 36.00 Bil | 36.40 Bil | 36.80 Bil | 0 | Affirmed | Guidance: 36.40 Bil for 2026 | |
| 2026 Operating Income | Calculated | 17.16 Bil | 18.05 Bil | 18.94 Bil | Rev x Gross Margin - Opex | |||
| 2026 Operating Margin | Calculated | 26.07% | 27.18% | 28.27% | Implied by guided Rev/GM/Opex | |||
| 2026 Non-GAAP Effective income tax rate | Reported | 23.5% | 24.0% | 24.5% | 0 | Affirmed | Guidance: 24.0% for 2026 | |
| 2026 Non-GAAP EPS | Reported | 5.04 | 5.1 | 5.16 | 0.5% | Raised | Guidance: 5.08 for 2026 | |
Q4 2025 Earnings Reported 2/3/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 65.50 Bil | 66.25 Bil | 67.00 Bil | 2.3% | Higher New | Guidance: 64.75 Bil for 2025 | |
| 2026 Non-GAAP Gross Margin | Reported | 82.0% | ||||||
| 2026 Non-GAAP Operating Expenses | Reported | 35.90 Bil | 36.40 Bil | 36.90 Bil | 39.2% | Higher New | Guidance: 26.15 Bil for 2025 | |
| 2026 Non-GAAP Effective Tax Rate | Reported | 23.5% | 24.0% | 24.5% | 9.5% | Higher New | Guidance: 14.5% for 2025 | |
| 2026 EPS | Reported | 5 | 5.08 | 5.15 | -43.3% | Lower New | Guidance: 8.96 for 2025 | |
Insider Activity
Updated 11/3/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Deluca, Richard R | EVP&Pres, Merck Animal Heallth | Direct | Sell | 8122026 | 131.63 | 11,699 | 1,539,992 | 14,501,792 | Form |
| 2 | Deluca, Richard R | EVP&Pres, Merck Animal Heallth | Direct | Sell | 8122026 | 131.76 | 12,837 | 1,691,426 | 16,057,293 | Form |
| 3 | Deluca, Richard R | EVP&Pres, Merck Animal Heallth | Direct | Sell | 8122026 | 130.43 | 20,784 | 2,710,951 | 17,569,928 | Form |
| 4 | Deluca, Richard R | EVP&Pres, Merck Animal Heallth | Direct | Sell | 8102026 | 130.38 | 6,050 | 788,773 | 20,271,727 | Form |
| 5 | Guindo, Chirfi | EVP, Access, Policy & Comms | Direct | Sell | 8072026 | 131.00 | 15,000 | 1,965,000 | 6,106,320 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Deluca, Richard R | EVP&Pres, Merck Animal Heallth | Direct | Sell | 8122026 | 131.63 | 11,699 | 1,539,992 | 14,501,792 | Form |
| 2 | Deluca, Richard R | EVP&Pres, Merck Animal Heallth | Direct | Sell | 8122026 | 131.76 | 12,837 | 1,691,426 | 16,057,293 | Form |
| 3 | Deluca, Richard R | EVP&Pres, Merck Animal Heallth | Direct | Sell | 8122026 | 130.43 | 20,784 | 2,710,951 | 17,569,928 | Form |
| 4 | Deluca, Richard R | EVP&Pres, Merck Animal Heallth | Direct | Sell | 8102026 | 130.38 | 6,050 | 788,773 | 20,271,727 | Form |
| 5 | Guindo, Chirfi | EVP, Access, Policy & Comms | Direct | Sell | 8072026 | 131.00 | 15,000 | 1,965,000 | 6,106,320 | Form |
| 6 | Maraldo, David R | EVP & Pres. MMD | Direct | Sell | 8072026 | 128.72 | 18,706 | 2,407,797 | 2,344,266 | Form |
| 7 | Williams, David Michael | EVP,Chief Info&Digital Officer | Direct | Sell | 8072026 | 128.77 | 52,847 | 6,805,145 | 4,084,096 | Form |
| 8 | Guindo, Chirfi | Chief Marketing Officer | Direct | Sell | 2122026 | 121.46 | 10,000 | 1,214,562 | 7,362,083 | Form |
| 9 | Guindo, Chirfi | Chief Marketing Officer | Direct | Sell | 2092026 | 118.41 | 10,000 | 1,184,101 | 8,361,544 | Form |
| 10 | Zachary, Jennifer | EVP, General Counsel | Direct | Sell | 2092026 | 119.15 | 121,573 | 14,485,690 | 8,211,454 | Form |
| 11 | Williams, David Michael | EVP,Chief Info&Digital Officer | Direct | Sell | 2062026 | 121.91 | 5,000 | 609,525 | 3,759,275 | Form |
| 12 | Oosthuizen, Johannes Jacobus | President, U.S. Market | Direct | Sell | 2062026 | 121.87 | 15,000 | 1,827,992 | 2,583,243 | Form |
| 13 | Deluca, Richard R | EVP&Pres, Merck Animal Heallth | Direct | Sell | 2062026 | 120.92 | 37,685 | 4,557,025 | 19,368,877 | Form |
| 14 | Guindo, Chirfi | Chief Marketing Officer | Direct | Sell | 2062026 | 121.88 | 20,000 | 2,437,676 | 9,825,678 | Form |
| 15 | Smart, Dalton E Iii | SVP Fin. - Global Controller | Direct | Sell | 2062026 | 119.67 | 6,400 | 765,920 | 981,911 | Form |
| 16 | Litchfield, Caroline | EVP & CFO | Direct | Sell | 2062026 | 119.61 | 41,997 | 5,023,312 | 10,787,997 | Form |
| 17 | Li, Dean Y | Executive VP & President, MRL | Direct | Sell | 2062026 | 118.77 | 15,087 | 1,791,824 | 12,146,215 | Form |
| 18 | Davis, Robert M | Chairman, CEO & President | Direct | Sell | 2062026 | 118.04 | 47,434 | 5,599,327 | 52,364,789 | Form |
| 19 | Downing, Cristal N | Chief Comm. & Public Afrs Ofcr | Direct | Sell | 11122025 | 87.00 | 7,085 | Form | ||
| 20 | Williams, David Michael | EVP,Chief Info&Digital Officer | Direct | Sell | 11042025 | 83.59 | 8,614 | 720,040 | 2,054,465 | Form |
Investor Activity (13F)
Updated Nov 5, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Atle Fund Management AB | $22.9 Mil | 7.4% | 39 | TRIM -82.7% | 13F |
| Sector Gamma AS | $31.3 Mil | 7.4% | 42 | TRIM -28.4% | 13F |
| Smead Capital Management, Inc. | $297.3 Mil | 6.5% | 32 | TRIM -12.9% | 13F |
| Kahn Brothers Group Inc | $27.3 Mil | 4.8% | 48 | TRIM -47.2% | 13F |
| SRB Corp | $55.7 Mil | 3.4% | 44 | Hold | 13F |
| Eldred Rock Partners, LLC | $13.1 Mil | 3.3% | 31 | Hold | 13F |
| Patient Square Capital LP | $9.6 Mil | 1.7% | 29 | New | 13F |
| Martin Investment Management, LLC | $5.7 Mil | 1.7% | 46 | Hold | 13F |
| Central Securities Corp | $18.0 Mil | 1.5% | 30 | Hold | 13F |
| Artia Global Partners LP | $5.6 Mil | 1.3% | 48 | New | 13F |
| Fairfax Financial Holdings LTD/ Can | $20.8 Mil | 1.1% | 29 | Hold | 13F |
| Blackhill Capital Inc | $20.3 Mil | 1.0% | 49 | Hold | 13F |
| Semper Augustus Investments Group LLC | $5.4 Mil | 0.6% | 44 | Hold | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | As Of | Filing |
|---|---|---|---|---|---|---|
| FengHe Fund Management Pte. Ltd. | $44.3 Mil | 2.5% | 38 | Exited | Dec 31, 2025 | 13F |
| Atle Fund Management AB | $22.9 Mil | 7.4% | 39 | TRIM -82.7% | Mar 31, 2026 | 13F |
| Kahn Brothers Group Inc | $27.3 Mil | 4.8% | 48 | TRIM -47.2% | Mar 31, 2026 | 13F |
| Sector Gamma AS | $31.3 Mil | 7.4% | 42 | TRIM -28.4% | Mar 31, 2026 | 13F |
| Smead Capital Management, Inc. | $297.3 Mil | 6.5% | 32 | TRIM -12.9% | Mar 31, 2026 | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Smead Capital Management, Inc. | $297.3 Mil | 6.5% | 32 | TRIM -12.9% | 13F |
| SRB Corp | $55.7 Mil | 3.4% | 44 | Hold | 13F |
| Sector Gamma AS | $31.3 Mil | 7.4% | 42 | TRIM -28.4% | 13F |
| Kahn Brothers Group Inc | $27.3 Mil | 4.8% | 48 | TRIM -47.2% | 13F |
| Atle Fund Management AB | $22.9 Mil | 7.4% | 39 | TRIM -82.7% | 13F |
| Fairfax Financial Holdings LTD/ Can | $20.8 Mil | 1.1% | 29 | Hold | 13F |
| Blackhill Capital Inc | $20.3 Mil | 1.0% | 49 | Hold | 13F |
| Central Securities Corp | $18.0 Mil | 1.5% | 30 | Hold | 13F |
| Eldred Rock Partners, LLC | $13.1 Mil | 3.3% | 31 | Hold | 13F |
| Patient Square Capital LP | $9.6 Mil | 1.7% | 29 | New | 13F |
| Martin Investment Management, LLC | $5.7 Mil | 1.7% | 46 | Hold | 13F |
| Artia Global Partners LP | $5.6 Mil | 1.3% | 48 | New | 13F |
| Semper Augustus Investments Group LLC | $5.4 Mil | 0.6% | 44 | Hold | 13F |
MRK Trade Sentinel
Constructive
CONVICTION RATIONALE
Conviction is constructive as Merck is successfully executing a massive portfolio pivot. The company recently raised its 2026 EPS guidance by 3.1% and is delivering critical pipeline wins, such as positive Phase 3 data for sac-TMT. New launches like Winrevair are accelerating, with 94% growth. This progress justifies the significant near-term margin pressure from strategic acquisitions needed to build the post-Keytruda business.
STOCK ARCHETYPE
Patent-Protected Franchise(Volume of drugs sold) x (Net realized price per drug), driven by new product launches, indication expansions for existing drugs, and market access/reimbursement. Gross margin generated from high-value, patent-protected drugs, particularly the blockbuster oncology therapy Keytruda.
INVESTMENT THESIS
Early evidence suggests yes, as clinical successes and strong new launches are validating the strategy.
- New drug Winrevair saw sales accelerate 94% year-over-year to $694 million in Q3 2026.
- Management identified a pipeline opportunity of over $70 billion by the mid-2030s.
- Full-year 2026 non-GAAP EPS guidance was raised by 3.1% at the new midpoint.
- Pipeline asset sac-TMT reduced risk of death by 32% in a recent Phase 3 trial.
- The company is on track to complete its stated $3 billion in share repurchases for the year.
PRIMARY RISK
The pipeline may fail to replace the massive revenue from Keytruda, which was 49% of 2025 sales, before its expected 2028-2029 loss of exclusivity, causing a structural decline in earnings.
- Keytruda is expected to face biosimilar competition between 2028 and 2029.
- Trailing-twelve-month operating margin has fallen to 9.2% from 34.9% a year ago.
- Management guided for 'modest revenue growth' in 2027, suggesting a slow near-term ramp.
- Keytruda sales growth is moderating, increasing 6% in Q3 2026, a slowdown from Q1 2026.
- There is a 'high rate of failure inherent in the research and development process'.
| KPI | Status | Rationale |
|---|---|---|
| Keytruda/Keytruda Qlex Sales Growth | Sales of $8.6 billion in Q3 2026, representing a 6% year-over-year increase. - Stable | Year-over-year growth is moderating in the mid-single digits, consistent with management commentary about approaching peak revenue in some indications. The latest quarter's 6% growth represents a slight re-acceleration from 4% in the prior quarter but remains below the 8% rate from two quarters ago. |
| Winrevair Sales Growth | Sales of $694 million in Q3 2026, representing a 94% year-over-year increase. - Accelerating | As a key new launch, Winrevair is demonstrating strong, accelerating growth both year-over-year and sequentially. The YoY growth rate increased from 75% in Q2 to 94% in Q3, driven by strong patient demand and new patient starts. |
| Trailing-Twelve-Month Revenue Growth | 4.9% year-over-year (TTM ended 9/30/2026) | Overall top-line growth rate of the company over the past year. |
| Latest-Quarter Revenue Growth | 4.7% year-over-year (Q3 2026 (ended 9/30/2026)) | The most recent quarterly revenue growth momentum, indicating current business trajectory. |
| Trailing-Twelve-Month Operating Margin | 9.2% (TTM ended 9/30/2026) | Core profitability after all operating expenses. The significant drop from 34.9% a year prior reflects a massive increase in operating expenses, including charges for acquisitions. |
Pipeline Promise vs. Margin Collapse
BULL VIEW
The 9.2% operating margin is a temporary, strategic investment to acquire a pipeline with a $70 billion opportunity. New launches are already accelerating, proving the strategy is working.
CORE TENSION
Can the accelerating ramp of new products like Winrevair (94% growth) and pipeline wins justify the collapse in operating margin to 9.2% from 34.9% a year prior?
PREVAILING SENTIMENT
The latest evidence favors the bull case. The market rewarded raised 2026 guidance and positive clinical data with a strong positive reaction to the most recent earnings report.
BEAR VIEW
The margin collapse reflects overpaying for assets in a desperate attempt to fill the Keytruda gap. The new portfolio will not ramp fast enough to prevent a major revenue decline post-2028.
| Timeline | Event & Metric To Watch |
|---|---|
second half of 2026 | Keytruda Combo PDUFA Decision Watch: FDA announcement regarding the supplemental Biologics License Applications (sBLAs) for this combination therapy. |
January 1, 2027 | German Pricing Law Effective Watch: A German healthcare reform law (GKV-BStabG) with significant cost-containment measures impacting the pharmaceutical industry takes effect. |
1/26/2027 - 2/3/2027 | Peer Earnings Sector Read-Through Watch: Peer commentary on US pricing environment, IRA impact, vaccine market trends, and demand in key therapeutic areas. |
2/1/2027 | PFE Earnings Report Watch: Peer Pfizer (PFE) scheduled to report earnings. |
2/2/2027 | Earnings Headwind From Purchase Timing Watch: Q4 revenue results versus consensus and management commentary on the unwind's actual impact versus this expectation. |
2/2/2027 | German Pricing Pressure Materializes Watch: Initial 2027 guidance, specifically commentary on European growth expectations and the quantified impact of German policy. |
2/3/2027 | BMY Earnings Report Watch: Peer Bristol Myers Squibb (BMY) scheduled to report earnings. |
June 29, 2027 | Lagevrio EUA Termination Watch: The declaration supporting Emergency Use Authorizations (EUAs) for COVID-19 products, including Lagevrio, is scheduled to terminate. |
the first half of 2027 | Sac-TMT Combo Phase Three Watch: Initiation of Phase 3 studies for sacituzumab tirumotecan (sac-TMT) in combination with MK-2020 (PD-1/VEGF bispecific) in first-line non-small cell lung cancer. |
| Date | Event | Stock Impact |
|---|---|---|
2026-10-29 | Reports Q3 Results and Raises Guidance Details: On October 29, 2026, Merck reported Q3 results, raising full-year 2026 guidance for sales by 0.4% and non-GAAP EPS by 3.1%. The stock reacted positively, rising 6.0% over two days. | +6.1% $140.93 -> $149.52 |
2026-10-26 | Positive Sac-TMT Endometrial Cancer Data Details: On October 26, 2026, the company announced that Sacituzumab Tirumotecan (Sac-TMT) reduced the risk of death by 32% in the Phase 3 TroFuse-005 trial for advanced or recurrent endometrial cancer. | -2.4% $145.27 -> $141.82 |
2026-09-25 | I-DXd Lung Cancer BLA Withdrawn Details: On September 25, 2026, Merck and partner Daiichi Sankyo announced the voluntary withdrawal of the Biologics License Application for ifinatamab deruxtecan (I-DXd) for extensive-stage small cell lung cancer. | +0.5% $147.98 -> $148.69 |
2026-08-06 | Enflonsia sBLA Accepted by FDA Details: On August 6, 2026, the company announced the FDA accepted a supplemental Biologics License Application for Enflonsia to expand its RSV indication for a second season in high-risk children. | +0.2% $127.58 -> $127.83 |
2026-07-10 | FDA Approves Keytruda Bladder Cancer Combo Details: On July 10, 2026, the FDA approved Keytruda and Keytruda Qlex, each in combination with Padcev, as a treatment for adults with muscle-invasive bladder cancer. | -0.8% $124.34 -> $123.30 |
2026-06-22 | Positive Tulisokibart Phase Three Data Details: On June 22, 2026, Merck announced positive topline results from the Phase 3 ATLAS-UC induction-only study for tulisokibart in patients with moderately to severely active ulcerative colitis. | +5.0% $113.20 -> $118.90 |
2026-05-22 | Stock Jumps On Oncology News Details: Shares rose 5% on May 22, 2026, after the company reported positive developments across multiple oncology programs, reinforcing confidence in its efforts to extend the dominance of Keytruda. | +3.3% $114.38 -> $118.17 |
Position Sizing
4% - 6%
NORMAL POSITION
Sizing is volatility-based: MRK trades at roughly 35% annualized realized (three-month) volatility versus about 10% for the S&P 500 (3.6x the market). A 4% - 6% position keeps a single-name swing of that size within a diversified portfolio's risk budget.
Diversification Alternatives
LLY - Eli Lilly
High-Growth InnovatorEli Lilly offers exposure to the highest-growth segments of the pharmaceutical market, with 45.5% TTM revenue growth and a 51.3% operating margin, far outpacing Merck's current performance.
ABBV - AbbVie
High-Margin OperatorAbbVie demonstrates superior operational efficiency, posting a 36% TTM operating margin on a similar revenue base to Merck's. This provides a more stable, high-profitability profile.
A pharmaceutical giant in a high-stakes race to build a new, diversified portfolio of blockbuster drugs before its primary profit engine, Keytruda, loses patent protection.
Merck's investment thesis hinges on the successful execution of its massive pipeline to offset the eventual, significant revenue loss from its top-selling cancer drug, Keytruda, which faces biosimilar competition post-2028. The company is aggressively investing in R&D and acquisitions, leading to near-term margin pressure, to bring forward over 20 new products. Recent positive clinical data and strong launches for new drugs like Winrevair are providing early validation of this strategy, but the scale of the challenge remains immense.
Positive Phase 3 data for key pipeline assets like sac-TMT, tulisokibart, and a recently discussed product; strong commercial uptake of new launches like Winrevair, Ohtuvayre, and LIPFENDRA; and successful label expansions for Keytruda.
Clinical trial failures for late-stage pipeline assets, slower-than-expected commercial launches, greater-than-expected pricing pressure from the IRA, or adverse patent litigation outcomes.
Minor quarterly sales fluctuations for mature products, early-stage pipeline announcements without data, or market rumors about M&A.
Repricing Catalyst
A series of anticipated clinical and regulatory milestones over the next 12 months, including Phase 3 data for tulisokibart (immunology), a recently discussed product (ophthalmology), islatravir (HIV), and potential approval for sac-TMT in endometrial cancer.
Pharmaceutical
$59.6B TTM (89% of Total)What It Is
This segment sells human health pharmaceutical and vaccine products, including therapeutic and preventive agents for human disorders. Key products include oncology drug Keytruda, HPV vaccine Gardasil, and diabetes drugs Januvia/Janumet. These are sold to drug wholesalers, retailers, hospitals, government agencies, and managed health care providers.
Who Pays & How
Wholesalers, retailers, hospitals, and government/managed care entities write the checks to acquire innovative medicines and vaccines that address unmet medical needs and improve patient outcomes.
Competition
Animal Health
$6.7B TTM (10% of Total)What It Is
This segment sells a wide range of veterinary pharmaceutical and vaccine products, as well as health management and monitoring solutions for livestock (cattle, swine, poultry) and companion animals. Products are sold to veterinarians, distributors, animal producers, farmers, and pet owners.
Who Pays & How
Veterinarians, distributors, and animal producers pay for products that prevent, treat, and control diseases in livestock and companion animals, ensuring animal health and production efficiency.
Competition
Merck — Investor Video Playlist
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Pharmaceuticals Resources |
| Fierce Pharma |
| Pharm Exec |
| Endpoints News |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.